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1. Introduction 
Obesity-driven type II diabetes mellitus has become a major crisis in modern societies. In the 
United States, over 80% of type II diabetic patients are obese [1]. In the case of Chinese adult 
diabetic patients, diabetes is also significantly associated with obesity [2]. Previous 
investigations have focused on looking for obesity-related factors that cause insulin resistance, 
the failure of the body to respond to insulin, which is the hallmark of type II diabetes. The 
abnormal plasma fatty acid metabolism associated with diabetes mellitus [3], and the high 
level of obesity-related plasma free fatty acids (FFAs, also known as non-esterified fatty acids, 
NEFA) have been identified since the 1950s as major risk factors for insulin resistance.  
Natural fatty acids are carboxylic acids with saturated or unsaturated aliphatic tails which 
have an even number of carbon atoms from 4 to 28. When they are not incorporated into other 
compounds, like triglyceride or phospholipids, they are known as "free" fatty acids. When 
metabolized, fatty acids yield a large quantity of ATP, and thus represent an important fuel for 
the body, particularly for heart and skeletal muscle. They are not only essential dietary 
nutrients, but also function in many cellular events by activating nuclear receptors, such as the 
peroxisome proliferator-activated receptors (PPARs), and fatty acid binding proteins (FABPs). 
How FFAs induce insulin resistance is not a novel topic in pathological studies on obesity-
associated type II diabetes. Many efforts have been made to uncover the underlying 
molecular mechanisms, but they remain elusive. It seems that FFA-induced insulin 
resistance occurs not via a single pathway but rather via a complicated network of pathways 
in organs, tissues, and cells.  
1.1. Acute cellular responses to Free Fatty Acids 
Major investigatons of the mechanisms of extra FFA-induced insulin resistance have focused 
on the chronic effects of FFAs. However, plasma FFA concentrations are not consistent and 
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vary widely from hour to hour, displaying waves according to nutritional state and the 
presence of regulators including hormones (Figure 1). The normal level of postprandial 
plasma FFAs is about 0.1- 0.4 mmol/L, while in obese individuals this value can reach to 0.2 
- 0.6 mmol/L [4]. In healthy people the level of plasma FFAs decreases during the 2 h after a 
meal until it drops to nearly 0.1 mmol/L, and then rises to a concentration of about 0.3-0.4 
mmol/L before the next meal. Such plasma FFA fluctuations also occur in people with 
metabolic disorders, but display a different pattern. In mild essential hypertensive patients, 
the plasma FFA concentrations at 3 and 4 h after a meal are significantly higher than that in 
healthy people (Figure 1, lower panel) [5]. The response of the body to acute variation in 
plasma FFA concentration is probably associated with the energy balance of the whole 
body, and requires further investigation to obtain a more in-depth understanding of the 
pathology of obesity-related metabolic diseases. 
 
Figure 1. Variation in free fatty acids (●) and insulin (○) concentrations in response to meals in healthy 
people (upper panel, reprinted from Frayn KN, 1998) [6] and fatty acid levels in mild essential 
hypertensive patients (---) and normotensive control subjects (——) (lower panel, reprinted from Singer 
P et al. 1985) [5]. 
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Previous works have reported that FFAs are able to acutely induce several cellular events in 
various tissues. For example, FFAs can stimulate insulin secretion in pancreatic β-cells [7, 8], 
leptin secretion in adipocytes [9], and glucose uptake in adipocytes and skeletal muscle cells 
[10, 11]. All these happen within a short interval after FFA treatment, implying that the 
FFAs may work as signaling molecules such as hormones, to trigger signal transduction and 
subsequent physiological events.  
During signal transduction, many intracellular signaling proteins work as  
molecular switches and are activated by GTP binding or phosphorylation. That FFAs 
acutely stimulate protein phosphorylation suggests that FFAs are able to evoke  
signal transduction. One study reports that arachidonic acid is able to stimulate the 
phosphorylation of tyrosine-containing proteins in cultured vascular endothelial  
and smooth muscle cells [12]; arachidonic acid-induced phosphorylation was rapid and 
transient, reaching a peak 0.5 min after the addition of arachidonic acid and returning to 
baseline by 8 min. When cyclooxygenase, lipoxygenase, and epoxygenase pathways  
were inhibited, phosphorylation was still detected, suggesting it was fatty acid, not its 
metabolites that triggered the phosphorylation. In addition, increased protein  
tyrosine phosphorylation was also observed after treatment with oleic, linolenic and γ-
linoleic acid. In another work it was reported that unsaturated fatty acids are able to 
stimulate protein phosphorylation by activating protein kinase C in intact  
hippocampal slices [13]. Oleic acid stimulated phosphorylation of several proteins of 
molecular weights 92,000, 58,000, 50,000, 47,000 and 44,000 Da. The 44,000 and  
47,000 Da proteins were particularly sensitive to fatty acids and were phosphorylated  
in a dose- and time-dependent manner. Increased 32P incorporation into the  
44,000 Da protein was apparent after 1 min and reached a maximum at 5 min. 
Phosphorylation of the 47,000 Da protein followed a similar pattern. Studies on fatty acid-
stimulated protein phosphorylation have shed light on the role of fatty acids as signal 
molecules. 
1.2. Free Fatty Acid Receptors 
During the last decade, a series of free fatty acid receptors (FFARs) has been identified, 
indicating that like other extracellular signal molecules, FFAs bind to their receptors on 
the plasma membrane to trigger signal transduction. The FFARs identified belong to a 
large protein family, the G protein-coupled receptors (GPCRs), which are  
integral membrane proteins with seven trans-membrane domains. The extracellular parts 
of the receptors sense external signals and activate heterotrimeric G proteins to transduce 
signals to downstream molecules. GPCRs are activated by various types of  
ligands, including ions, nucleotides, amino acids, lipids, peptides, and proteins. It is 
estimated that more than half of modern drugs target these receptors [14]. The known 
FFARs include FFAR1 (GPR40), FFAR2 (GPR43), FFAR3 (GPR41), GPR84, GPR119 and 
GPR120 (Table 1).  
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Protein Tissue Expression Ligand Function 
Synthetic 
Agonist 
G protein-
coupling 
GPR 40 
(FFAR1) 
Pancreatic β 
 
-cell [15, 16], 
intestinal tract [17], 
muscle[16], brain, 
monocytes [18] 
Medium- and 
long- C8-C22 
[18, 15] 
Insulin secretion 
[15]; incretin 
secretion [17] 
Thiazolidinedi
one [16], 
GW9508, 
MEDICA16 
[18] 
Gq/11, Gi 
[15, 16] 
GPR 41 
(FFAR3) 
Adipose tissue [9], 
sympathetic 
ganglia [19], 
enteroendocrine 
cells [20] 
Short C2-C4 [9]
Leptin secretion [9]; 
PYY secretion [20] 
/ Gi/o [19, 21] 
GPR 43 
(FFAR2) 
Leukocyte, spleen, 
bone marrow, 
adipose tissue [22] 
Short C2-C4 
[21] 
5-HT secretion; PYY 
secretion [23]; 
inhibition of 
lipolysis [24] 
/ 
Gq/11, Gi/o 
[21] 
GPR 84 
Immune cell, bone 
marrow, leukocyte, 
lung, lymph node, 
spleen [25, 26] 
Medium C9-
14C [26] 
Amplify IL-12 p40 
[27] 
/ Gi/o [26] 
GPR 119 
Brain, 
gastrointestinal 
tract, pancreas [28] 
Ethanolamide 
[28], 
Lysophosphati
dyl choline [29]
Insulin secretion 
[29]; food intake; 
body weight [28] 
PSN632408, 
PSN37569 [30],  
AR23145 [31] 
Gs [29] 
GPR 120 
Intestinal tract, 
Macrophage, lung, 
adipose tissue [32, 
33] 
Medium- and 
long- C10-C22 
[32] 
GLP-1 secretion [32]
NCG21 [34], 
GW9508 [35] 
Gq/11 [32] 
Table 1. Characteristic of FFARs.  
It has been reported that GPR40 is activated by medium- and long-chain FFAs [18, 15, 16]. 
GPR40 is abundantly expressed in the pancreas, and is especially enriched in pancreatic β-
cells. When activated by FFAs, GPR40 activates G-protein, which transduces the signal 
leading to stimulation of insulin secretion. Using Chinese hamster ovary (CHO) cells in 
which GPR40 is stably expressed, Itoh et al. found that free fatty acids are able to stimulate 
the formation of inositol 1,4,5-trisphosphate, intracellular Ca2+ mobilization, and the 
phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 [15]. Furthermore, in 
2006 Feng et al. reported that fatty acids, especially linoleic acid, are able to stimulate insulin 
secretion in rat β-cells by reducing the voltage-gated K+ current via GPR40 and the cAMP-
protein kinase A system [36]. 
Unlike GPR40, the physiological ligands of GPR41 and GPR43 are short chain fatty acids 
(SCFAs), including acetate (C2), propionate (C3), butyrate (C4), and valerate (C5). SCFAs are 
generated by bacterial fermentation of undigested carbohydrates from ingested dietary fiber 
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in the gut. Subsequently SCFAs are released in the bloodstream and accumulate to 
micromolar concentrations. 
GPR41 is expressed abundantly in adipose tissue, enteroendocrine cells, and sympathetic 
ganglia. SCFAs activate GPR41 and stimulate leptin expression in mouse adipocytes and 
mouse primary-cultured adipocytes. Acute oral administration of propionate increases 
circulating leptin levels in mice [9]. Overexpression of exogenous GPR41 and knockdown of 
GPR41 by RNAi regulates leptin production positively and negatively. Given that leptin is a 
potent anorexigenic hormone that reduces food intake, propionate may inhibit food intake 
by increasing leptin release. The analysis of GPR41-deficient mice showed that GPR41 is 
expressed in enteroendocrine cells, and GPR41 deficiency is associated with reduced 
expression of PYY [20]. GPR41 is also abundantly expressed in sympathetic ganglia in mice 
and humans [19]. Studies using GPR41-/- mice and co-culturing of fetal-isolated 
cardiomyocytes with primary-cultured sympathetic neurons have shown that propionate 
promotes sympathetic outflow via GPR41, reduces intracellular cAMP concentrations and 
promotes ERK1/2 phosphorylation, phenomena which were not observed in sympathetic 
neurons from GPR41−/− mice. GPR41-mediated rise in beat rate was effectively blocked by 
Gallein (Gβγ blocker) and pertussis toxin (PTX) treatments, whereas NF023 (Gα(i/o) blocker) 
had no inhibitory effects. Knockdown of PLCβ 2/3 or ERK1/2 by RNAi significantly inhibits 
the propionate-induced rise in the beat rate of cardiomyocytes. These results indicate that 
GPR41 activation of sympathetic neurons may involve Gβγ, PLCβ, and MAPK. 
GPR43 is highly expressed in immune cells, spleen, and bone marrow, and is also detected 
at low levels in the placenta, lung, liver, and adipose tissues [22]. A study on adipocytes 
showed that acetate and propionate can reduce lipolytic activity and thus plasma FFA level 
in a mouse in vivo model. This inhibition of lipolysis is abolished in adipocytes isolated from 
GPR43 knockout animals [24]. Similar to GPR41, GPR43 activation is also coupled to 
intracellular Ca2+ release, ERK1/2 activation, and a reduction in cAMP accumulation. Unlike 
GPR41, however, which signals via the Gi/o family, GPR43 signals via both the Gi/o and Gq 
pathways [21].  
GPR84 mRNA is expressed mainly in bone marrow, leukocytes, the spleen and lung [25, 26]. 
GPR84 functions as a receptor for medium-chain FFAs with carbon chain lengths of 9–14. 
Capric acid (C10:0), undecanoic acid (C11:0), and lauric acid (C12:0) are the most potent 
agonists of GPR84. A functional study conducted in GPR84-/- mice revealed that primary 
stimulation of T cells with anti-CD3 results in increased IL-4, but not IL-2 or IFN-γ 
production, compared to wild-type mice [27]. Wang et al. reported that medium-chain FFAs 
act through GPR84 to amplify the stimulation of IL-12 p40 production by 
lipopolysaccharides in monocytes/macrophages [26]. Medium-chain FFAs induce Ca2+ 
mobilization and inhibit cAMP production. The activation of GPR84 by medium-chain FFAs 
is primarily coupled to a PTX-sensitive Gi/o pathway [26]. 
GPR119 in humans and rodents is expressed predominantly in the pancreas and 
gastrointestinal tract and also in the rodent brain [28]. The lipid signaling agent 
oleoylethanolamide (OEA) is an endogenous ligand of GPR119. OEA is a peripherally acting 
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agent that reduces food intake and body weight gain in rat feeding models, suggesting that 
GPR119 might mediate the OEA-induced reduction of food intake [28]. Lysophosphatidyl 
choline (LPC) is another bioactive lipid mediator that activates GPR119 to stimulate insulin 
release from pancreatic islets, via Gs activation which leads to cAMP production [29].  
GPR120 is highly expressed in the human and mouse intestinal tract, as well as in 
adipocytes, taste buds, and lungs [32, 33]. GRP120 activation by saturated FFAs with a 
carbon chain length of 14–18, and by unsaturated FFAs with a chain length of 16–22 has 
been detected [32]. Activated by medium- and long- chain fatty acids, GPR120 increases 
insulin secretion indirectly by stimulating the secretion of glucagon-like peptide-1 (GLP-1), 
the most potent insulinotropic incretin, which is coupled to the elevation of Ca2+ and 
activation of the ERK cascade [32]. In addition, GPR120 is also reported to function as an ω-3 
FA receptor in proinflammatory macrophages and mature adipocytes that mediates the 
potent anti-inflammatory effects of DHA and EPA by inhibiting both the TLR and TNF- 
inflammatory signaling pathways [37]. Chronic tissue inflammation is another important 
mechanism causing insulin resistance, so the effect of GPR120 on insulin sensitivity as well 
as on the stimulation of insulin-secretion will make it an attractive drug target for diabetes-
therapeutic agents. 
The discovery of FFARs developed our understanding of the role of FFAs as signal 
molecules. Cells expressing FFARs, such as pancreatic β-cells, adipocytes, and macrophages 
sense FFAs and make various corresponding responses to control metabolic homeostasis 
(Figure 2). FFARs have thus attracted considerable attention due to their potential as 
valuable drug targets. 
 
Figure 2. Roles of GPR40 and GPR120 in nutritional regulation. Free fatty acid receptors control 
metabolism through promoting the secretion or production of peptide hormones (Reprinted from Hara 
et al., 2011) [38]. 
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In addition to the functions described above, FFAs are also able to acutely stimulate  
glucose uptake in adipocytes and skeletal muscle cells, which is directly associated with 
metabolic homeostasis. A few reports indicate that fatty acids have acute effects on glucose 
uptake, but conclusions have been inconsistent and the underlying molecular mechanisms 
controlling these responses are still elusive. For example, alpha-lipoic acid has been  
shown to enhance basal glucose uptake both in normal and ob/ob mice [10], while palmitic 
acid (PA) treatment was reported to inhibit insulin-stimulated but not basal glucose uptake 
[11].  
Although both adipocytes and skeletal muscle cells are able to ingest glucose by stimulation 
of FFAs, skeletal muscle consumes more than 70% of the plasma glucose, suggesting that 
whole body plasma glucose concentration is tightly associated to the sensitivity of muscle 
tissue to insulin [39, 40]. We therefore focused on the molecular mechanism of fatty acid-
induced glucose uptake in skeletal muscle cells [41]. 
2. Mechanism study on Free Fatty Acid acute stimulation of glucose 
uptake 
2.1. Palmitate stimulates glucose uptake, GLUT4 translocation, and 
phosphorylation of Akt, AMPK, and ERK1/2 in L6 cells 
A rat skeletal muscle cell line L6 with stable expression of myc-tagged GLUT4 (L6) was used 
to study the acute effects of fatty acids. When L6 cells were treated with palmitic acid (PA), 
the most abundant free fatty acid in the blood, glucose uptake increased rapidly in a time-
dependent manner, beginning from 5 min, and reaching a peak at 20 min (Figure 3, lower 
panel). By incubating intact PA-treated L6-GLUT4myc cells with myc antibody to detect 
plasma membrane-located GLUT4, we found that PA stimulates GLUT4 translocation from 
the cytosol to the plasma membrane (Figure 3, upper panel). The stimulatory effects of PA 
on glucose uptake and GLUT4 translocation are similar to those of insulin.  
Fluorescence imaging shows GLUT4 translocation to the cell surface after L6-GLUT4myc 
(L6) cells are treated with (upper right panel) or without (upper left panel) PA or insulin 
(upper middle panel). The lower panel shows that glucose uptake increases in a time-
dependent manner when L6 cells are treated with PA. 
Akt plays an important role in insulin-stimulated GLUT4 translocation and glucose uptake. 
Akt, also known as protein kinase B (PKB), is a serine/threonine-specific protein kinase. Akt 
possesses a protein domain known as the PH domain, which binds to phosphoinositides. 
Binding to PIP3, and phosphorylated from PIP2 by PI3 Kinase (PI3K) via its PH domain, Akt 
can be phosphorylated by phosphoinositide dependent kinase 1 (PDK1) at threonine 308 
and/or the mammalian target of rapamycin complex 2 (mTORC2) at serine 473. In the 
insulin signaling pathway, the insulin receptor (IR) is activated and tyrosine is 
phosphorylated after binding to insulin, subsequently activating hte IRS-1/PI3K/PDK/Akt 
cascade, and finally increasing the level of GLUT4 in the plasma membrane (Figure 4). 
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Figure 3. Palmitate stimulates GLUT4 translocation and glucose uptake [41]. 
 
Figure 4. Insulin signaling pathway for glucose uptake stimulation (Reprinted from Frøsig and  
Richter, 2009) [42]. 
In our study, PA stimulated Akt phosphorylation at serine 473 in a time- and dose-
dependent manner (Figure 5). During PA treatment, Akt phosphorylation was detected after 
10 min, peaked at 45 min, then decreased dramatically after 1 h, and became nondetectable 
 
Fatty Acids Stimulate Glucose Uptake by the PI3K/AMPK/Akt and PI3K/ERK1/2 Pathways 137 
after 3 h. When treated with different concentrations of PA, Akt phosphorylation increased 
with PA concentration, beginning from 0.2 mM. Such time- and dose-dependent responses 
to PA treatment in cells match the characteristics of signal transduction, and so it is possible 
that a signal transduction cascade initiated by PA leads to the activation of Akt. To further 
verify the stimulatory effect of PA on Akt activation, we treated rat skeletal muscle tissue 
with PA. Rats were anesthetized and perfused with 2 mM PA. Skeletal muscle strips were 
collected and then incubated in vitro with PA. Similar to the results from cells, Akt 
phosphorylation also increased in PA-treated skeletal muscle tissue, suggesting that this 
acute response of PA may be physiologically relevant. 
 
Figure 5. Palmitate acutely stimulates AMPK and Akt phosphorylation in a time- and dose-dependent 
manner [41]. 
To investigate the putative PA-mediated signaling pathway, we tested the activity of other 
molecules and found that AMP-activated protein kinase (AMPK) and extracellular signal-
related kinase (ERK1/2) can also be activated by acute PA treatment. AMPK is a 
heterotrimeric complex composed of a catalytic α subunit and regulatory β and γ subunits, 
which together make a functional enzyme that plays a role in cellular energy homeostasis 
[43]. AMPK is activated by an elevated AMP/ATP ratio and undergoes a conformational 
change of its γ subunit to expose the active site (Thr172) on the catalytic subunit α that is 
phosphorylated by the upstream kinase AMPK kinase (AMPKK) [44]. Upon activation, 
AMPK decreases energy consumption by inhibiting fatty acid and protein synthesis and 
enhances energy production by stimulating fatty acid oxidation and glucose transport to 
increase cellular energy levels. While it is known that AMPKα is phosphorylated at Thr258 
and Ser485, its upstream kinases still need further study [45]. ERK1/2 belongs to the 
mitogen-activated protein kinase (MAPK) family, a widely conserved family of 
serine/threonine protein kinases. The ERK1/2 (p44/42 MAPK) signaling pathway responds 
to various extracellular stimuli including mitogens, growth factors, and cytokines [46]. Upon 
activation by MEK1 and MEK2 by phosphorylation of its Thr202 and Tyr204 residues, 
respectively, ERK1/2 phosphorylates downstream targets, forming a signal cascade. 
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Similar to Akt, AMPK in L6 cells is also activated acutely by PA. AMPK phosphorylation 
(Thr172) starts as early as 5 min after PA treatment and reaches a peak at 20 min. After 1 h, 
the signal cannot be detected (Figure 5, upper panel). In addition, PA-induced 
phosphorylation of AMPK is also dose-dependent. Unlike Akt and AMPK, ERK1/2 is 
phosphorylated for a shorter duration, increasing after 5 min and returning to basal level 
after 15 min (Figure 6). 
 
Figure 6. Palmitate acutely stimulates ERK1/2 phosphorylation in a time-dependent manner [41]. 
2.2. Akt, AMPK and ERK1/2 are involved in PA-stimulated glucose uptake 
To test if Akt, AMPK, and ERK1/2 are involved in PA-stimulated glucose uptake, tools such 
as inhibitors, dominant negative constructs, and short interference RNA (siRNA) were used 
to inhibit their protein activity or expression levels. Western blotting and glucose uptake 
assay results showed that all of these proteins participate in signal transduction. 
We applied API-2, an Akt selective inhibitor, to block Akt activity. As a result, API-2 
abolished Akt phosphorylation as well as significantly decreasing PA-induced glucose 
uptake (Figure 7, left panel). In addition, siRNA duplexes were nucleofected into L6 cells; 
compared to the negative control (N.C.), total Akt expression level was efficiently down-
regulated. Glucose uptake assays showed that PA-induced glucose uptake decreased when 
Akt expression decreased due to RNAi (Figure 7, right panel). Together, these data suggest 
that PA induces glucose uptake in skeletal muscle cells via Akt activation. 
To study the role of AMPK in PA-induced glucose uptake, we used AMPK inhibitor 
Compound C, an myc-tagged AMPK dominant negative (AMPK-DN) plasmid, and siRNA 
targeting AMPK catalytic subunits α1 and α2. Since AMPK and Akt activation was observed 
sequentially in PA-treated cells, we also examined the relationship between AMPK and Akt. 
AMPK inhibitor Compound C suppressed AMPK activity and decreased PA-induced Akt 
phosphorylation and glucose uptake (Figure 8, left panel). Similar results were obtained 
when AMPK-DN was nucleofected into L6 cells. Furthermore, an siRNA duplex mixture 
targeting AMPK α decreases PA-stimulated Akt phosphorylation in L6 cells (Figure 8, right 
panel), consistent with the inhibitor and AMPK-DN experiments.  
In contrast, when AMPK agonist AICAR was used to stimulate AMPK phosphorylation, Akt 
was also stimulated rapidly in a time-dependent manner (Figure 9), suggesting that it is 
possible to stimulate Akt via AMPK activation in L6 cells. These data suggest that PA-
stimulated AMPK phosphorylation may contribute to regulating Akt activity and is 
involved in PA-induced glucose uptake. 
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Figure 7. PA-induced glucose uptake is decreased when Akt activity is blocked by an Akt inhibitor (left 
panel) or RNAi (right panel) [41]. 
 
 
 
Figure 8. PA-induced glucose uptake and Akt phosphorylation is decreased when AMPK activity is 
reduced by an AMPK inhibitor (left panel) or AMPK dominant-negative construct (right panel) [41]. 
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Figure 9. AMPK agonist AICAR stimulates Akt phosphorylation in a time-dependent manner [41]. 
The role of ERK1/2 in PA-stimulated signal transduction was examined by using the 
MEK1/2 inhibitors PD98056 and U0126. While both inhibitors decreased basal and PA-
induced ERK1/2 phosphorylation, U0126 was more potent (Figure 10, upper left). When 
ERK1/2 activity was inhibited by U0126, PA-induced glucose uptake was reduced 
significantly (Figure 10, upper right). These data suggest that PA-stimulated ERK1/2 
phosphorylation may contribute to PA-induced glucose uptake. To determine the 
relationship between ERK1/2 and the AMPK/Akt pathway, AMPK α1/α2 siRNA transfected 
cells were used to test ERK1/2 activity; ERK1/2 phosphorylation increased at the same rate 
as in N.C. cells after PA treatment (Figure 10, lower left). In addition, the Akt inhibitor API-2 
did not affect PA-induced ERK1/2 phosphorylation, and MEK1/2 inhibitors PD98056 and 
U0126 did not affect PA-induced Akt phosphorylation (Figure 10, lower right). These data 
suggest that ERK1/2 contributes to PA-stimulated signal transduction independently from 
the AMPK/Akt pathway, consistent with the partial decrease in PA-induced glucose uptake 
by inhibition of either Akt, AMPK, or ERK1/2. 
 
Figure 10. MEK1/2 inhibitors decrease PA-induced ERK1/2 phosphorylation and glucose uptake, but 
do not affect Akt activity; AMPK and Akt activity inhibition does not affect ERK1/2, while PI3K 
inhibitor does [41]. 
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Having shown that the two pathways work independently in PA-induced glucose uptake in 
L6 cells, we investigated signaling molecules upstream of the intersection. When we used 
PI3 Kinase (PI3K) -specific inhibitor LY294002 to treat L6 cells, PA-induced glucose uptake 
was totally abolished (Figure 11, upper panel), suggesting that PI3K may control these two 
pathways. Indeed, LY294002 could abolish PA-stimulated AMPK, Akt, and ERK1/2 
phosphorylation (Figure 10, lower right and Figure 11, lower panel). Results from the above 
experiments indicate that, in skeletal muscle cell lines and tissues, acute PA-stimulated 
glucose uptake occurs via activation of the PI3K/AMPK/Akt and PI3K/ERK1/2 pathways 
leading to GLUT4 translocation (Figure 12). 
 
Figure 11. PI3K-specific inhibition abolishes PA-induced glucose uptake and phosphorylation of Akt 
and AMPK [41]. 
 
Figure 12. Schematic diagram of PA-induced signal pathway stimulation of acute glucose uptake in 
skeletal muscle cells [41]. 
 Protein Phosphorylation in Human Health 142 
2.3. Palmitate stimulates Akt phosphorylation via binding to the plasma 
membrane 
As shown in Figure 12, how PA activates PI3K is still unknown. According to our current 
understanding of signal transduction, we speculate that PA may bind to a protein on the cell 
plasma membrane to trigger signal transduction. We performed fatty acid binding assays to 
test this hypothesis. 
L6 cells were incubated with PA at low temperature (4°C) to facilitate PA binding to the cell 
surface while preventing its internalization, then washed with buffer to remove unbound 
PA, or with BSA solution to remove not only unbound but also some membrane-bound PA 
by competitive binding, Cells were then transferred to 37°C to recover cellular activity. The 
amount of PA which binds to the cell surface was measured by adding trace amounts of 3H-
labeled PA to the solution. Results showed that after washing, with either buffer or BSA 
solution, very little PA remained (Figure 13, upper panel). When these cells were transferred 
to 37°C, Western blot results showed that Akt phosphorylation took place at a similar level 
to that in cells kept at 37°C, and increased in a time-dependent manner in buffer-washed 
cells, while p-Akt was not detectable in BSA solution-washed cells (Figure 13, lower panel). 
These results suggest that the amount of cell surface-bound PA was sufficient to activate 
Akt; intracellular PA accumulation was not required. Moreover, based on lipid analysis by 
TLC, fatty acids were the main component of total lipids during cell treatment with fatty 
acid and the 10 min incubation at 37°C. These results indicate that it is fatty acids rather than 
their metabolites that trigger signal transduction . 
 
Figure 13. Cell plasma-bound PA stimulates Akt phosphorylation [41]. 
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3. Future work 
Could the postulated cell membrane protein which binds to FFAs and triggers signal 
transduction to stimulate glucose uptake in skeletal muscle cells be a G-protein coupled 
receptor? FFA binding assays suggest that PA initiates signal transduction via a protein(s) 
on the cell surface, and meanwhile in the FFA-stimulated signal cascade ERK1/2 pathways 
were involved, which also appeared in some known FFAR signal pathways. Therefore, a 
GPCR on the plasma membrane of skeletal muscle cells may be the FFA receptor we have 
postulated.  
PA is a long-chain fatty acid with 16 carbons. We tested other long-chain fatty acids such as 
C18:1 (oleic acid), C18:2 (Linoleic acid), and C18:0 (Stearic acid) in addition to PA to examine 
their effects of stimulating AMPK and Akt phosphorylation. All of these fatty acids 
activated AMPK and Akt in a time- and dose-dependent manner. It is thus likely that our 
postulated FFAR may function using long-chain FFAs as its ligands.  
The known long-chain FFARs include GPR40 and GPR120, both of which are related to 
insulin secretion. Oh et al. found that GPR120 agonists DHA and GW9508 enhance 
glucose uptake by activating the PI3K-Akt pathway and GLUT4 translocation in 3T3-L1 
adipocytes. The stimulatory effect of DHA and GW9508 was blocked when GPR120 or 
Gαq/11 was depleted by siRNA knockdown [37], indicating that FFAs stimulate glucose 
uptake in adipocytes via the FFA receptor GPR120. However, neither GPR120 nor GPR40 
is expressed in muscles. In the Oh et al. study, DHA and GW9508 did not enhance glucose 
uptake in L6 skeletal muscle cells. We therefore conclude that known long-chain FFARs 
GPR40 and GPR120 are not our postulated FFA receptor. In 2005, Gaël Jean-Baptiste et al. 
described the GPCRs expressed in skeletal muscle tissue, but none of them are FFA 
receptors [47]. Our postulated receptor might therefore be a novel FFAR whose function is 
to stimulate glucose uptake in skeletal muscle tissue. Like GPR40 and GPR120, our 
postulated FFAR is also related to metabolic homeostasis, and so it is likely to be a 
potential drug target for the treatment of diabetes. Identification of this FFAR is one of 
our goals. 
Another significant implication of our results is that PA plays two opposing roles in skeletal 
muscle. Under chronic treatment it inhibits insulin-stimulated glucose uptake by blocking 
Akt phosphorylation, while it enhances glucose uptake by activating Akt when cells are 
exposed to PA for a short time. What is the relationship between the long-term and short-
term effects of FFAs on glucose uptake? Our results show that phosphorylation of Akt is 
only stimulated when the concentration of PA reached a certain level (at or above 0.2 
mmol/L in C2C12 cells). We thus conclude that phosphorylation of Akt may require high 
concentrations of fatty acids under physiological situations. Akt phosphorylation is not 
detectable 3 h after fatty acid treatment (Figure 5, upper panel). In addition, when fatty acids 
are withdrawn, the Akt phosphorylation signal disappears after 3 h in C2C12 cells (data not 
shown), suggesting that fatty acid-induced phosphorylation and dephosphorylation of Akt 
can be completed within one cycle of a postprandial FFA wave. It is therefore possible that 
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Akt phosphorylation and dephosphorylation occur again and again as the concentration of 
FFA increases and decreases. Plasma FFA concentration starts to rise from 2 h after a meal 
(Figure 1) and continues to rise until the next meal due to the release of FFA from 
adipocytes during fasting. Based on our findings, when increasing plasma FFA reaches a 
certain level it stimulates Akt phosphorylation and glucose uptake. In obesity patients, 
elevated plasma FFA probably reaches the FFA level triggering Akt phosphorylation earlier 
during a plasma FFA wave, leading to abnormal glucose uptake. Many abnormal fatty acid 
cycles may contribute to the development of insulin resistance by disturbing glucose 
homeostasis. This Yin-Yang balance of PA in skeletal muscle is likely to be physiologically 
significant, and the possibility of its involvement in the development of insulin resistance 
needs to be investigated further. 
4. Conclusion 
Free fatty acids (FFAs) function as signal molecules by activating their receptors in the cell 
plasma membrane to evoke signal transduction by a series of protein phosphorylation 
events, eventually leading to physiological events. Some of the known cell responses to 
FFAs are directly or indirectly related to metabolic homeostasis, so the study of FFA-
triggered signal transduction will help us to understand the development of metabolic 
disorders and to design strategies for therapy. FFA receptors have become attractive drug 
targets for metabolic diseases. We have investigated the mechanism of long-chain fatty acid 
palmitate-induced glucose uptake in skeletal muscle cells and found that the two 
independent PI3K/AMPK/Akt and PI3K/ERK1/2 pathways are responsible for this process. 
Our results also provide supporting evidence that palmitate triggers signal transduction via 
a cell surface protein(s) that is probably a novel FFA receptor whose identity still remains to 
be determined. 
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